Literature DB >> 8896424

VH and VL gene analysis in sporadic Burkitt's lymphoma shows somatic hypermutation, intraclonal heterogeneity, and a role for antigen selection.

C J Chapman1, J X Zhou, C Gregory, A B Rickinson, F K Stevenson.   

Abstract

Tumor cell lines and one tumor biopsy from seven cases of Epstein-Barr virus (EBV) genome-negative sporadic Burkitt's lymphoma (BL) have been investigated for usage and mutational pattern of Ig variable region genes. The VH genes were derived from the VH 3 (one) and VH4 (six) families and both the IgM-positive (six) and the IgA-positive (one) were all mutated from their germline counterparts. The VL genes were derived from V kappa 1 (one), V kappa 3 (one), V lambda 1 (four), and V lambda 2 (one) families and were also somatically hypermutated. Biopsy material from one of the IgM-positive cases showed VH and VL sequences that matched the derived cell line, with additional intraclonal sequence heterogeneity, indicating that the tumor cells had undergone posttranformation somatic mutation. Mutational patterns in V(H) genes did not show a conventional role for antigen in selecting tumor cell sequences. In contrast, patterns in VL sequences were consistent with a role for antigen in five of seven cases. The pattern of extensive scattered somatic hypermutation and intraclonal variation is similar to that in VH sequences of EBV genome-positive endemic BL, although the degree of mutational activity is less. These common features indicate that B cells involved in the two variants of BL may share a common clonal history.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8896424

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

1.  Inhibition of Fas-mediated apoptosis by antigen: implications for lymphomagenesis.

Authors:  Elaine J Schattner; Steven M Friedman; Paolo Casali
Journal:  Autoimmunity       Date:  2002-07       Impact factor: 2.815

Review 2.  Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities.

Authors:  Nicholas Chiorazzi; Manlio Ferrarini
Journal:  Blood       Date:  2010-12-09       Impact factor: 22.113

3.  Problems in using statistical analysis of replacement and silent mutations in antibody genes for determining antigen-driven affinity selection.

Authors:  Biplab Bose; Subrata Sinha
Journal:  Immunology       Date:  2005-10       Impact factor: 7.397

Review 4.  Somatic hypermutation and B-cell lymphoma.

Authors:  D Dunn-Walters; C Thiede; B Alpen; J Spencer
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-01-29       Impact factor: 6.237

5.  Analysis of the expressed immunoglobulin variable region heavy chain gene products in paraproteins from Iranian patients with multiple myeloma.

Authors:  S Gharagozloo; R A Sharifian; R A Mageed; F Shokri
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

6.  The Epstein-Barr virus nuclear antigen-1 promotes genomic instability via induction of reactive oxygen species.

Authors:  Bettina Gruhne; Ramakrishna Sompallae; Diego Marescotti; Siamak Akbari Kamranvar; Stefano Gastaldello; Maria G Masucci
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-12       Impact factor: 11.205

7.  Sequence analysis of V(4-34)-encoded antibodies from single B cells of two patients with systemic lupus erythematosus (SLE).

Authors:  C I Mockridge; C J Chapman; M B Spellerberg; B Sheth; T P Fleming; D A Isenberg; F K Stevenson
Journal:  Clin Exp Immunol       Date:  1998-10       Impact factor: 4.330

Review 8.  Epstein-Barr virus and Burkitt lymphoma.

Authors:  G Brady; G J MacArthur; P J Farrell
Journal:  J Clin Pathol       Date:  2007-12       Impact factor: 3.411

9.  Burkitt lymphoma: pathogenesis and immune evasion.

Authors:  Jason M God; Azizul Haque
Journal:  J Oncol       Date:  2010-10-05       Impact factor: 4.375

10.  Frequent occurrence of highly expanded but unrelated B-cell clones in patients with multiple myeloma.

Authors:  Jitra Kriangkum; Sarah N Motz; Carina S Debes Marun; Sandrine T Lafarge; Spencer B Gibson; Christopher P Venner; James B Johnston; Andrew R Belch; Linda M Pilarski
Journal:  PLoS One       Date:  2013-05-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.